Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer

Clinical patterns and the associated optimal management of acquired resistance to PD-(L)1 blockade are poorly understood. All cases of metastatic lung cancer treated with PD-(L)1 blockade at Memorial Sloan Kettering were reviewed. In acquired resistance (complete/partial response per RECIST, followe...

Full description

Bibliographic Details

Published in:	Clinical cancer research Vol. 28; no. 17; p. 3797
Main Authors:	Schoenfeld, Adam J, Rizvi, Hira A, Memon, Danish, Shaverdian, Narek, Bott, Matthew J, Sauter, Jennifer L, Tsai, C Jillian, Lihm, Jayon, Hoyos, David, Plodkowski, Andrew J, Perez-Johnston, Rocio, Sawan, Peter, Egger, Jacklynn V, Greenbaum, Benjamin D, Rimner, Andreas, Riely, Gregory J, Rudin, Charles M, Rusch, Valerie W, Gomez, Daniel R, Hellmann, Matthew D
Format:	Journal Article
Language:	English
Published:	United States 01.09.2022
Subjects:	B7-H1 Antigen Biomarkers, Tumor - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Humans Immunotherapy Lung Neoplasms - pathology Tumor Burden
ISSN:	1557-3265, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!